Sanofi-a Ventis Deutschland Gmbh

Hoechst Aktiengesellschaft

Sanofi

Sanofi-aventis

Hoechst Marion Roussel Deutschland Gmbh

Georg Tschank

Ulrich Werner

Gerhard Jaehne

Karl Schoenafinger

Christian Buning

Martin Bickel

Elisabeth Defossa

Kurt Ritter

Torsten Haack

Stefan Guessregen

Christian Engel

Thomas Boehme

Karl-Heinz Baringhaus

Klaus Weidmann

Dietrich Brocks

Volkmar Gunzler

Jurgen Mohr

Hartmut Hanauske-Abel

Stephan Henke

Harald Burghard

Holger Wagner

Guenter Mueller

Rudolf Schneider

Lothar Schwink

Paul Habermann

Norbert Tennagels

Gunter Muller

Gerhard Seipke

Mark Sommerfeld

Marc Korn

Roland Kurrle

Holger Gaul

Guenter Billen

Kari I Kivirikko

Gerhard Kretzschmar

Marcus Korn

Günter Müller

Marc Dietrich Voss

Kari Majamaa

Marcus Hermann Korn

Elizabeth Defossa

Christian Bunning

The invention relates to novel insulin analogs having a basal time-action profile, which are characterized by the following features: a) the B chain end consists of an amidated basic amino acid residue such as lysine or arginine amide; b) the N-terminal amino acid residue of the insulin A chain is a lysine or arginine radical; c) the amino acid position A8 is occupied by a histidine radical; d) the amino acid position A21 is occupied by a glycine radical; and e) one or more substitutions and/or additions of negatively charged amino acid residues are carried out in the positions A5, A15, A18, B-1, B0, B1, B2, B3 and B4.

Insulin derivatives having an extremely delayed time-action profile

The invention relates to the compounds of formula (I) and physiologically acceptable salts thereof. The compounds are suitable, e.g., for treating hyperglycemia. 

Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof

The invention relates to the compounds of formula (I) and to the physiologically acceptable salts thereof. Said compounds are suitable e.g. for the treatment of hyperglycemia. 

Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof

Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof

The invention relates to the compounds of formula (I) and to the physiologically acceptable salts thereof. Said compounds are suitable for the treatment of hyperglycemia. 

Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof

The invention relates to compounds of formula (I) and to the physiologically compatible salts thereof. Said compounds are suitable, for example, for treating hyperglycemia. 

Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof

Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof

Disclosed is a benzyl-oxathiazine derivative, as shown in Formula I, the derivative being substituted with adamantane or noradamantane: the variables of which are as described herein; also disclosed is a method of preparation and use of same.

Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof

Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof

The invention relates to novel insulin analogs having a basal time-action profile, which are characterized by the addition and/or substitution of negatively and positively charged amino acid residues and by an amidation of the C-terminal carboxy group of the B chain and histidine in position 8 of the insulin A chain. The invention also relates to the production and use thereof.

The invention relates to isolated nucleic acid molecules and to host cells comprising such nucleic acid molecules. Moreover, the invention relates to a polypeptide having PIM-3 activity and having a definite amino acid sequence, as well as to the use of PIM-3 as a screening agent for identifying anti-type 2 diabetes mellitus drugs and for preparing a medicament for the treatment of insulin resistance or type 2 diabetes mellitus.

PIM-3 kinase as a target for type 2 diabetes mellitus

The invention 8-aminothioxanthines and the derivatives of formula I wherein the various R groups and substituents are comprised of a number of different (C-C)-alkyl, cycloalkyl, aryl, alkene, alkyne, etc. groups and derivatives thereof which are hereinafter more specifically defined for the treatment of metabolic disorders such as type-2 diabetes, hyperglycemia, arteriosclerotic diseases and the like.

Substituted 8-aminoalkylthioxanthines, and their use as inhibitors of dipeptidyl peptidase IV

The present invention comprises the use of amino-substituted 8-N-benzimidazoles compounds of formula I wherein R3, R4-R5, R11 and R20-R21 are hereinafter defined which display a therapeutically utilizable blood sugar-lowering action. These compounds are intended to be particularly suitable in the treatment of diabetes.

Amide-substituted 8-N-benzimidazoles, method for the production thereof, and use of the same as medicaments

The present invention comprises the use of amino-carbonyl-substituted 8-N-benzimidazoles compounds of formula I wherein R3, R4-R5, R11 and R20-R21 are hereinafter defined which display a therapeutically utilizable blood sugar-lowering action. These compounds are intended to be particularly suitable in the treatment of diabetes, carbohydrate and lipid metabolic disorders and other blood sugar complications.

Aminocarbonyl-substituted 8-N-benzimidazoles, methods for their preparation and their use in pharmaceutical compositions

Growing community of inventors

Essenheim, Germany

Georg Tschank